The pharmaceutical industry faces a stark environment of rising costs and stagnant drug innovation that will ensure more acquisitions are done, as drugmakers try to offset painful and growing business pressures, GlaxoSmithKline's chief strategy officer said. Report
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments